Stem cells in breast tumours: Are they ready for the clinic?

European Journal of Cancer

Volumn 48, Issue 14, 2012, Pages 2104-2116

  Ablett, Matthew P ^a   Singh, Jagdeep K ^a   Clarke, Robert B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Breast cancer; Cancer stem cells; Stem cells; Therapy resistance

Indexed keywords

CD34 ANTIGEN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; INTERLEUKIN 8; PACLITAXEL;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CELL DIFFERENTIATION; CELL DIVISION; CELL SURFACE; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84865494894     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.03.019     Document Type: Article

References (107)

1. M.F. Clarke, J.E. Dick, and P.B. Dirks Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res 66 19 2006 9339 9344
2. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 7 1997 730 737
3. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells Proc Nat Acad Sci USA 100 7 2003 3983 3988
4. M.S. Wicha, S. Liu, and G. Dontu Cancer stem cells: an old idea - a paradigm shift Cancer Res 66 4 2006 1883 1890 [discussion 1895-1896]
5. C.M. Fillmore, and C. Kuperwasser Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy Breast Cancer Res 10 2 2008 R25
6. K. Polyak Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev 3 2 2007 107 109
7. P.C. Nowell The clonal evolution of tumor cell populations Science 194 4260 1976 23 28
8. R.P. Hill Identifying cancer stem cells in solid tumors: case not proven Cancer Res 66 4 2006 1891 1895 [discussion 1890]
9. J.M. Adams, P.N. Kelly, A. Dakic, S.L. Nutt, and A. Strasser Response to comment on "tumor growth need not be driven by rare cancer stem cells" Science 318 2007 1722d
10. E. Quintana, M. Shackleton, and M.S. Sabel Efficient tumour formation by single human melanoma cells Nature 456 7222 2008 593 598
11. G. Dontu, M. Al-Hajj, W.M. Abdallah, M.F. Clarke, and M.S. Wicha Stem cells in normal breast development and breast cancer Cell Prolif 36 Suppl. 1 2003 59 72
12. D. Ponti, A. Costa, and N. Zaffaroni Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties Cancer Res 65 13 2005 5506 5511
13. T.M. Phillips, W.H. McBride, and F. Pajonk The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation J Natl Cancer Inst 98 24 2006 1777 1785
14. C. Sheridan, H. Kishimoto, and R.K. Fuchs CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis Breast Cancer Res 8 5 2006 R59
15. G.J. Bauerschmitz, T. Ranki, and L. Kangasniemi Tissue-specific promoters active in CD44+CD24-/low breast cancer cells Cancer Res 68 14 2008 5533 5539
16. G. Honeth, P.O. Bendahl, and M. Ringner The CD44+/CD24- phenotype is enriched in basal-like breast tumors Breast Cancer Res 10 3 2008 R53
17. P.J. Keller, A.F. Lin, and L.M. Arendt Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines Breast Cancer Res 12 5 2010 R87
18. H. Harrison, G. Farnie, and S.J. Howell Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor Cancer Res 70 2 2010 709 718
19. A. Howell, and A.M. Wardley Overview of the impact of conventional systemic therapies on breast cancer Endocr Relat Cancer 12 Suppl. 1 2005 S9 S16
20. C. Ginestier, M.H. Hur, and E. Charafe-Jauffret ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 5 2007 555 567
21. F. Yu, H. Yao, and P. Zhu Let-7 regulates self renewal and tumorigenicity of breast cancer cells Cell 131 6 2007 1109 1123
22. X. Li, M.T. Lewis, and J. Huang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 9 2008 672 679
23. C.J. Creighton, X. Li, and M. Landis Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Nat Acad Sci USA 106 33 2009 13820 13825
24. S. Chuthapisith, J. Eremin, M. El-Sheemey, and O. Eremin Breast cancer chemoresistance: emerging importance of cancer stem cells Surg Oncol 19 1 2010 27 32
25. M. Diehn, R.W. Cho, and N.A. Lobo Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 458 7239 2009 780 783
26. W.A. Woodward, M.S. Chen, and F. Behbod WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells Proc Nat Acad Sci USA 104 2 2007 618 623
27. R.L. Atkinson, M. Zhang, and P. Diagaradjane Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy Sci Transl Med 2 55 2010 55ra79
28. M.L. Asselin-Labat, M. Shackleton, and J. Stingl Steroid hormone receptor status of mouse mammary stem cells J Natl Cancer Inst 98 14 2006 1011 1014
29. K.E. Sleeman, H. Kendrick, and D. Robertson Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland J Cell Biol 176 1 2007 19 26
30. R.B. Clarke, A. Howell, C.S. Potten, and E. Anderson Dissociation between steroid receptor expression and cell proliferation in the human breast Cancer Res 57 22 1997 4987 4991
31. K.B. Horwitz, W.W. Dye, J.C. Harrell, P. Kabos, and C.A. Sartorius Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts Proc Nat Acad Sci USA 105 15 2008 5774 5779
32. P. Kabos, J.M. Haughian, and X. Wang Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers Breast Cancer Res Treat 128 1 2010 45 55
33. R.A. McClelland, D. Barrow, and T.A. Madden Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex) Endocrinology 142 7 2001 2776 2788
34. J.M. Knowlden, I.R. Hutcheson, and H.E. Jones Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 3 2003 1032 1044
35. C. Wright, S. Nicholson, and B. Angus Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer Br J Cancer 65 1 1992 118 121
36. G. Farnie, R.B. Clarke, and K. Spence Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways J Natl Cancer Inst 99 8 2007 616 627
37. J. Zhou, H. Zhang, and P. Gu NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells Breast Cancer Res Treat 111 3 2008 419 427
38. H. Korkaya, A. Paulson, F. Iovino, and M.S. Wicha HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 27 47 2008 6120 6130
39. A. Magnifico, L. Albano, and S. Campaner Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab Clin Cancer Res 15 6 2009 2010 2021
40. S. Paik, C. Kim, and N. Wolmark HER2 status and benefit from adjuvant trastuzumab in breast cancer N Engl J Med 358 13 2008 1409 1411
41. H. Joensuu, P.L. Kellokumpu-Lehtinen, and P. Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 8 2006 809 820
42. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 2005 1673 1684
43. P.B. Gupta, C.M. Fillmore, and G. Jiang Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells Cell 146 4 2011 633 644
44. C.L. Chaffer, I. Brueckmann, and C. Scheel Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state Proc Nat Acad Sci USA 108 19 2011 7950 7955
45. G. Dontu, K.W. Jackson, and E. McNicholas Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells Breast Cancer Res 6 6 2004 R605 R615
46. A. Androutsellis-Theotokis, R.R. Leker, and F. Soldner Notch signalling regulates stem cell numbers in vitro and in vivo Nature 442 7104 2006 823 826
47. H. Al-Husaini, D. Subramanyam, M.J. Reedijk, and S.S. Sridhar Notch signaling pathway as a therapeutic target in breast cancer Mol Cancer Ther 10 1 2010 9 15
48. J. Jiang, and C.C. Hui Hedgehog signaling in development and cancer Dev Cell 15 6 2008 801 812
49. S. Liu, G. Dontu, and I.D. Mantle Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res 66 12 2006 6063 6071
50. N.D. Lawson, A.M. Vogel, and B.M. Weinstein Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation Dev Cell 3 1 2002 127 136
51. M. Kakarala, D.E. Brenner, and H. Korkaya Targeting breast stem cells with the cancer preventive compounds curcumin and piperine Breast Cancer Res Treat 122 3 2010 777 785
52. M.L. Guzman, S.J. Neering, and D. Upchurch Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells Blood 98 8 2001 2301 2307
53. L. Malaguarnera, M.R. Pilastro, and R. DiMarco Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate Apoptosis 8 5 2003 539 545
54. S.C. Larsson, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 4 2007 856 862
55. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 7503 2005 1304 1305
56. B. Liu, Z. Fan, and S.M. Edgerton Metformin induces unique biological and molecular responses in triple negative breast cancer cells Cell Cycle 8 13 2009 2031 2040
57. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and K. Struhl Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res 69 19 2009 7507 7511
58. A. Vazquez-Martin, C. Oliveras-Ferraros, S.D. Barco, B. Martin-Castillo, and J.A. Menendez The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Breast Cancer Res Treat 126 2 2010 355 364
59. Thompson AM, Iwamoto T, Jordan L, Purdie C, Bray SE, Baker L, et al. Final analysis of the NEOMET trial of neoadjuvant metformin: examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. In: 2011 ASCO Annual Meeting. J Clin Oncol 2011;29:2011 (Suppl.; abstr 534).
60. C. Ginestier, J. Wicinski, and N. Cervera Retinoid signaling regulates breast cancer stem cell differentiation Cell Cycle 8 20 2009 3297 3302
61. G.T. Budd, P.C. Adamson, and M. Gupta Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer Clin Cancer Res 4 3 1998 635 642
62. L. Altucci, and H. Gronemeyer The promise of retinoids to fight against cancer Nat Rev Cancer 1 3 2001 181 193
63. J.A. Lawrence, P.C. Adamson, and R. Caruso Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations J Clin Oncol 19 10 2001 2754 2763
64. S. Zhou, J.D. Schuetz, and K.D. Bunting The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype Nat Med 7 9 2001 1028 1034
65. L. Patrawala, T. Calhoun, and R. Schneider-Broussard Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic Cancer Res 65 14 2005 6207 6219
66. Y. Zhong, C. Zhou, and W. Ma Most MCF7 and SK-OV3 cells were deprived of their stem nature by Hoechst 33342 Biochem Biophys Res Commun 364 2 2007 338 343
67. A.H. Schinkel, J.J. Smit, and O. van Tellingen Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 4 1994 491 502
68. H.C. Cooray, C.G. Blackmore, L. Maskell, and M.A. Barrand Localisation of breast cancer resistance protein in microvessel endothelium of human brain Neuroreport 13 16 2002 2059 2063
69. Y. An, and W.M. Ongkeko ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5 12 2009 1529 1542
70. W.N. Hittelman, Y. Liao, L. Wang, and L. Milas Are cancer stem cells radioresistant? Future Oncol 6 10 2010 1563 1576
71. F. Karimi-Busheri, A. Rasouli-Nia, J.R. Mackey, and M. Weinfeld Senescence evasion by MCF-7 human breast tumor-initiating cells Breast Cancer Res 12 3 2010 R31
72. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. In: 2009 ASCO Annual Meeting. J Clin Oncol 2009;27:18s (Suppl.; abstr CRA501).
73. H. Calvert, and A. Azzariti The clinical development of inhibitors of poly(ADP-ribose) polymerase Ann Oncol 22 Suppl. 1 2009 i53 i59
74. J. O'Shaughnessy, C. Osborne, and J.E. Pippen Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 3 2011 205 214
75. P. Domagala, J. Lubinski, and W. Domagala Iniparib in metastatic triple-negative breast cancer N Engl J Med 364 18 2011 1780 [author reply 1781]
76. N.R. Monks, D.K. Biswas, and A.B. Pardee Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target J Cell Biochem 92 4 2004 646 650
77. Z. Madjd, A.Z. Mehrjerdi, and A.M. Sharifi CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours Cancer Immun 9 2009 4
78. J. Rom, G. von Minckwitz, and W. Eiermann Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study Ann Oncol 19 10 2008 1698 1705
79. J. Rom, G. von Minckwitz, and F. Marme Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer Ann Oncol 20 11 2009 1829 1835
80. K. Miyake, K.L. Medina, and S. Hayashi Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures J Exp Med 171 2 1990 477 488
81. E. Marangoni, N. Lecomte, and L. Durand CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts Br J Cancer 100 6 2009 918 922
82. J.L. Guan Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer IUBMB Life 62 4 2010 268 276
83. L.V. Owens, L. Xu, and R.J. Craven Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors Cancer Res 55 13 1995 2752 2755
84. H.M. Lightfoot Jr., A. Lark, and C.A. Livasy Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis Breast Cancer Res Treat 88 2 2004 109 116
85. M. Luo, H. Fan, and T. Nagy Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells Cancer Res 69 2 2009 466 474
86. P.P. Provenzano, D.R. Inman, K.W. Eliceiri, H.E. Beggs, and P.J. Keely Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer Am J Pathol 173 5 2008 1551 1565
87. H. Lahlou, V. Sanguin-Gendreau, and D. Zuo Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression Proc Nat Acad Sci USA 104 51 2007 20302 20307
88. T. Nagy, H. Wei, and T.L. Shen Mammary epithelial-specific deletion of the focal adhesion kinase gene leads to severe lobulo-alveolar hypoplasia and secretory immaturity of the murine mammary gland J Biol Chem 282 43 2007 31766 31776
89. A. Schultze, and W. Fiedler Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer Expert Opin Invest Drugs 19 6 2010 777 788
90. E. Charafe-Jauffret, C. Ginestier, and F. Iovino Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature Cancer Res 69 4 2009 1302 1313
91. M. Huang, Y. Li, H. Zhang, and F. Nan Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction J Exp Clin Cancer Res 29 2010 80
92. D. Iliopoulos, H.A. Hirsch, G. Wang, and K. Struhl Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion Proc Nat Acad Sci USA 108 4 2011 1397 1402
93. M.S. Wicha Regulation of breast cancer stem cells by cytokine networks Mol. Targets Cancer Ther. 10 11 Suppl. 1 2011
94. C. Ginestier, S. Liu, and M.E. Diebel CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts J Clin Invest 120 2 2010 485 497
95. S. Liu, C. Ginestier, and S.J. Ou Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks Cancer Res 71 2 2011 614 624
96. S.Y. Park, H.E. Lee, and H. Li Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer Clin Cancer Res 16 3 2010 876 887
97. R. Liu, X. Wang, and G.Y. Chen The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 3 2007 217 226
98. S. Pece, D. Tosoni, and S. Confalonieri Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content Cell 140 1 2010 62 73
99. M. Cristofanilli, G.T. Budd, and M.J. Ellis Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 8 2004 781 791
100. M.H. Wright, A.M. Calcagno, and C.D. Salcido Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics Breast Cancer Res 10 1 2008 R10
101. M. Cariati, A. Naderi, and J.P. Brown Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line Int J Cancer 122 2 2008 298 304
102. M.J. Meyer, J.M. Fleming, and A.F. Lin CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer Cancer Res 70 11 2010 4624 4633
103. A.M. Calcagno, C.D. Salcido, and J.P. Gillet Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics J Natl Cancer Inst 102 21 2010 1637 1652
104. C. Lagadec, E. Vlashi, and L. Della Donna Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment Breast Cancer Res 12 1 2010 R13
105. M. Zhang, F. Behbod, and R.L. Atkinson Identification of tumor-initiating cells in a p53-null mouse model of breast cancer Cancer Res 68 12 2008 4674 4682
106. T. Hoey, W.C. Yen, and F. Axelrod DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency Cell Stem Cell 5 2 2009 168 177
107. M. Kubo, M. Nakamura, and A. Tasaki Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer Cancer Res 64 17 2004 6071 6074